All Oncology News

UCSF researchers have discovered that the cells of triple-negative breast cancer tumors build molecular tunnels into nearby fat cells.

Experts preview key abstracts to watch at the IASLC 2025 World Conference on Lung Cancer.

Tari A. King, MD, FACS, FSSO, FASCO, discusses locoregional breast cancer management strategies and avoiding lymph node dissection in select patients.

C. Ola Landgren, MD, PhD, discusses the feasibility of daratumumab plus KRd as a standard of care for the management of newly diagnosed multiple myeloma.

Palbociclib hit the primary end point of disease control in a phase 2 study of patients with advanced chordoma harboring p16 and/or CDKN2A loss.

Neoadjuvant sacituzumab govitecan plus pembrolizumab with adjuvant/maintenance pembrolizumab led to high cCR rates in MIBC.

The European Commission approved neoadjuvant tislelizumab plus chemotherapy, followed by adjuvant tislelizumab, for resectable non–small cell lung cancer.

The addition of abemaciclib to endocrine therapy after surgery improved OS in patients with HR-positive, HER2-negative breast cancer with positive nodes.

Following cuts to federal funding for health agencies, concerns about the long-term consequences for research programs in the US are escalating.

William C. Huang, MD, discusses the FDA approval of UGN-102 for the treatment of patients with recurrent, low-grade, intermediate-risk NMIBC.

UM171 cell therapy has earned European Commission approval for the treatment of patients with hematologic malignancies requiring HSCT.

Ivonescimab plus chemotherapy improved overall survival in previously treated, advanced non–small cell lung cancer harboring EGFR mutations.

Jessica Paulus, ScD, discusses the incorporation of an external control arm into the analysis of a phase 2 trial in HER2-positive breast cancer.

R. Lor Randall, MD, FACS, discusses prosthetic design, embodiment strategies, and research to enhance function post-amputation in sarcoma management.

Trastuzumab deruxtecan has been approved in Japan for patients with HR+, HER2-low or -ultralow metastatic breast cancer.

New tool by Yale researchers charts journey from pre-cancerous to advanced disease in animal models.

Stenoparib receives FDA fast track designation for the treatment of patients with advanced ovarian cancer.

The emergence of immunotherapies and targeted agents has ushered in a new era in relapsed/refractory multiple myeloma.

The FDA has granted breakthrough therapy designation to rinatabart sesutecan for the treatment of patients with advanced or recurrent endometrial cancer who have disease progression on or following standard-of-care therapy.

Eric K. Singhi, MD, and Shruti Patel, MD, discuss how they extend beyond the walls of their clinic to provide accurate cancer updates on social media.

Jonathan Leventhal, MD, discusses the prevalence of breast cancer treatment–associated dermatologic AEs and the need for multidisciplinary management.

David Olmos, MD, PhD, discusses how data on the incidence of HRR alterations in metastatic prostate cancer can inform future research.

Meletios A. Dimopoulos, MD, discusses the efficacy and safety of elranatamab plus daratumumab and lenalidomide in transplant-ineligible multiple myeloma.

A study finds cancer cells break down protective nerve coverings, leading to nerve injury and chronic inflammation.

Rusfertide earned an FDA breakthrough designation for polycythemia vera based on findings from the phase 3 VERIFY study.

Datopotamab deruxtecan is approved in China for hormone receptor–positive, HER2-negative metastatic breast cancer after prior endocrine therapy and chemotherapy.

Versamune HPV plus pembrolizumab improved OS vs historical data with pembrolizumab in HPV16-positive metastatic HNSCC with a CPS of at least 1.

Marina Kremyanskaya, MD, PhD, discusses the investigation of divesiran in polycythemia vera.

To extend the benefits of CTLA-4 inhibitors to poorly immunogenic tumors such as HCC and CRC, investigators are developing Fc-enhanced CTLA-4 inhibitors.

Shahzad Raza, MD, discusses updated outcomes with talquetamab and teclistamab in relapsed/refractory multiple myeloma with extramedullary disease.